1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Akari Hopes Tick-Based Drug Will Be Safer, Cheaper Than Alexion's Soliris

 
• By Sten Stovall

Akari Therapeutics is looking to ticks to provide a new therapy that it hopes will offer a safer and cheaper alternative to Alexion Pharmaceuticals' Soliris for some rare orphan diseases.

Tick

NASDAQ-listed Akari Therapeutics PLC –which has a pipeline of tick-derived molecules selected to suppress mediators of chronic inflammation in wide range of orphan disorders – expects a Phase II topline data readout soon for its lead candidate that it hopes will open the way for Phase III trialing later this year in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH).

Akari’s lead molecule is Coversin, a recombinant small protein (16,740 Da) derived from a native protein discovered in the saliva...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.